The role of CD133 expression of cancer stem cells on radiotherapy response in early stage glottic cancers
- PDF / 757,481 Bytes
- 6 Pages / 595.276 x 790.866 pts Page_size
- 66 Downloads / 121 Views
LARYNGOLOGY
The role of CD133 expression of cancer stem cells on radiotherapy response in early stage glottic cancers Emrah Gülmez1 · Imdat Yüce2 · Mete Gündoğ3 · Özlem Canöz4 · Kerem Kökoğlu2 · Alperen Vural2 · Sedat Çağlı2 Received: 28 March 2020 / Accepted: 3 June 2020 © Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Purpose To investigate the relationship between CD133 positivity and radiotherapy (RT) response in early stage glottic laryngeal cancers. Methods Thirty seven patients with early-stage glottic laryngeal carcinoma who were treated with primary RT were evaluated. Patients with regular follow-up of at least 3 years were included in the study. Patients who had previously received chemotherapy for laryngeal surgery or underwent surgery were excluded. The patients were divided into two groups as recurrent and non-recurrent. These two groups were compared in terms of CD133 expression by immunohistochemical method. Results There were 37 patients in the study. Ten patients had recurrence and seven (70%) had CD133 positive and three had CD133 negative. Of 27 patients who had no recurrence, 16 (59%) had CD133 positive and 11 (41%) had CD133 negative. 7 (70%) of ten patients with recurrence were found to be positive for CD133; There was no statistically significant difference between recurrent and non-recurrent patient groups in terms of CD133 positivity (p > 0.05). There was no correlation between the final CD133 score and recurrence status as well (p > 0.05). Conclusion There was no relationship between radiotherapy response and CD133 staining in early-stage glottic laryngeal cancers. It is the largest study about CD133 and RT sensitivity in early stage glottic carcinomas. Keywords CD133 · Cancer stem cell · Laryngeal cancer · Radiotherapy · AC133 clone
Introduction Laryngeal cancer is a common type of head and neck cancer, comprising 25% of cases. 55–75% of laryngeal cancers develop from the glottic area. Radiotherapy (RT) or surgery can be performed separately in the treatment of early stage glottic cancers. Although cure rates are high in early stage glottic carcinoma, the optimal treatment choice is still controversial [1].
* Kerem Kökoğlu [email protected] 1
Department of Otolaryngology, Elazığ Fethi Sekin City Hospital, Elâzığ, Turkey
2
Department of Otolaryngology ‑ Head and Neck Surgery, Faculty of Medicine, Erciyes University, Kayseri, Turkey
3
Department of Radiation Oncology, Faculty of Medicine, Erciyes University, Kayseri, Turkey
4
Department of Pathology, Faculty of Medicine, Erciyes University, Kayseri, Turkey
Cancer stem cells, which are able to renew themselves and differentiate to many kinds of distinct cells, are subgroups of cancer cells [2]. It is also known that initiative cells cause cancer [3]. CD 133, which is known as prominin, is a cancer stem cell marker. It is a ∼120-kDa glycoprotein. It has a N-terminal extracellular domain, two large extracellular loops, and an intracellular C-terminus [4]. The expression of CD133 in cell lines
Data Loading...
